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Abstract
Background: Malignant ascites often develops in advanced stages of ovarian carcinoma, consisting
of single and aggregated tumor cells, or spheroids. Spheroids have commonly been used as tumor
models to study drug efficacy, and have shown resistance to some chemotherapies and radiation.
However, little is known about the adhesive or invasive capabilities of spheroids, and whether this
particular cellular component of the ascites can contribute to dissemination of ovarian cancer.
Here, we examined the invasive ability of ascites spheroids recovered from seven ovarian
carcinoma patients and one primary peritoneal carcinoma (PPC) patient.
Methods:  Ascites spheroids were isolated from patients, purified, and immunohistochemical
analyses were performed by a pathologist to confirm diagnosis. In vitro assays were designed to
quantify spheroid disaggregation on a variety of extracellular matrices and dissemination on and
invasion into normal human mesothelial cell monolayers. Cell proliferation and viability were
determined in each assay, and statistical significance demonstrated by the student's t-test.
Results: Spheroids from all of the patients' ascites samples disaggregated on extracellular matrix
components, with the PPC spheroids capable of complete disaggregation on type I collagen.
Additionally, all of the ascites spheroid samples adhered to and disaggregated on live human
mesothelial cell monolayers, typically without invading them. However, the PPC ascites spheroids
and one ovarian carcinoma ascites spheroid sample occasionally formed invasive foci in the
mesothelial cell monolayers, suggestive of a more invasive phenotype.
Conclusion: We present here in vitro assays using ascites spheroids that imitate the spread of
ovarian cancer in vivo. Our results suggest that systematic studies of the ascites cellular content are
necessary to understand the biology of ovarian carcinoma.
Background
Ovarian carcinoma is the most lethal cancer of the female
reproductive system. Despite decades of research, the
long-term survival rate for the disease is poor, with only
25% of patients diagnosed with stage III or IV ovarian can-
cer surviving beyond five years. Typically, 75% of patients
have advanced stage disease at the time of initial diagno-
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sis, due to an absence of symptoms and the lack of a reli-
able detection method in early stages of the disease [1].
Ovarian cancer spreads as tumor cells are shed from the
surface of the ovary into the peritoneal cavity. The tumor
cells can secrete vascular permeability factors and block
lymphatic drainage, leading to the accumulation of ascites
fluid [2-5]. Ovarian tumor cells sloughed into the ascites
can use the fluid as a means to seed the peritoneal cavity,
adhering to the mesothelial cells that line the peritoneum
and its organs. Once adhered, the tumor cells can subse-
quently invade, establishing tumors at secondary sites
often without the need to enter the vasculature. Within
the ascites, ovarian carcinoma cells that have not adhered
to the mesothelium can aggregate, forming spheroids.
Besides their spontaneous generation in the ascites of
ovarian cancer patients, spheroids can be created in vitro
from many different cell types for use as three-dimen-
sional tumor models. Research has shown that spheroids
tend to be resistant to some chemotherapies and radiation
therapy [6-13]. However, few studies have characterized
the adhesive or invasive abilities of spheroids, particularly
in ovarian cancer, leaving their contribution to dissemina-
tion unknown. Despite their undefined role, there is a
dearth of studies on cells isolated from ovarian carcinoma
effusions. However, previous studies with tumor cells
injected into murine models have shown that ascitic
tumor cells can penetrate the peritoneal surfaces [14-17].
In humans, it has not been determined whether cells
found free-floating in the ascites can be stimulated to
become invasive, or if only a few have metastatic poten-
tial.
Due to the nature of the multicellular aggregates, it is not
feasible to use standard assay techniques to quantitate
spheroid cell spreading and invasion. Because patient
ascites spheroids range in size, pre-labeling the spheroids
either fluorescently or radioactively does not allow differ-
entiation between one very large spheroid versus several
smaller spheroids, as both could yield the same output yet
give no information about the number of spheroids
present or morphologic information such as their change
in size. For this reason, we have designed spheroid assays
where the spheroids are counted manually and digitally
measured at the time of plating and again at each subse-
quent time-point, to quantitate the actual amount of
adhesion, migration, or invasion occurring. These novel
assays allow generation of quantitative spheroid data, and
are flexible enough to be modified to more closely mimic
the peritoneal environment.
Ovarian carcinoma ascites fluid is known to contain a
complex mix of secreted factors that can affect the cellular
environment of the tumor cells and the mesothelial cells
of the peritoneum. Secreted extracellular matrix (ECM)
molecules, cytokines, chemokines, proteases, vascular
permeability factors, and lysophosphatidic acid have all
been detected in the ascites fluid, and many of these mol-
ecules have been shown to enhance the growth of tumor
cells [18-21]. Considering the unique spread of ovarian
carcinoma, the relatively understudied role of the ascites
cellular content, and limited knowledge regarding sphe-
roid biology, a more comprehensive understanding of the
mechanisms of ovarian carcinoma dissemination is cru-
cial.
In previous studies, we demonstrated that spheroids iso-
lated from ovarian carcinoma patient ascites or created
from the NIH:OVCAR5 human ovarian carcinoma cell
line can adhere to ECM components and live mesothelial
cell monolayers [22,23]. We have also shown that
NIH:OVCAR5 spheroids are capable of complete disag-
gregation on type I collagen, and can invade live mesothe-
lial cell monolayers via β1 integrin interactions and the
production of proteases, resulting in foci of invasion 200-
fold larger than their initial size within one week [24]. In
this study, we continue to address the ability of spheroids
to contribute to the spread of ovarian carcinoma by exam-
ining the dissemination and invasion of patient ascites
spheroid samples in vitro.
Methods
Materials
Type IV collagen from mouse Engelbreth Holm-Swarm
(EHS) tumor was purchased from Trevigen (Gaithersburg,
MD). Type I collagen from human placenta was pur-
chased from Southern Biotech (Birmingham, AL). Mouse
EHS laminin was purchased from Invitrogen (Carlsbad,
CA). Human plasma fibronectin, purified as described,
was provided by Dr. James McCarthy, University of Min-
nesota[25] Human umbilical cord hyaluronan was pur-
chased from Sigma Chemical Co. (St. Louis, MO). Bovine
serum albumin was purchased from Pierce Biotechnology
(Rockford, IL).
Antibodies
CD 15 monoclonal antibody (mAb) MMA, CA-125 mAb
OV185:1, and CD45 mAb LCA were purchased from Ven-
tana Medical Systems (Tucson, AZ). B72.3 mAb was pur-
chased from Signet Laboratories, Inc. (Dedham, MA).
Polyclonal antibodies against CEA and a mAb against Ber-
EP4 were purchased from DakoCytomation (Carpinteria,
CA). A polyclonal antibody against calretinin was pur-
chased from Zymed Laboratories (South San Francisco,
CA).
Cell culture
The human peritoneal mesothelial cell line LP9 was pur-
chased from the Coriell Cell Repository (Camden, NJ),Journal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
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and maintained in a 1:1 ratio of M199 and MCDB110
media, supplemented with 15% fetal bovine serum (FBS),
2 mM glutamine, 5 ng/ml EGF, 0.4 µg/ml hydrocortisone,
and 50 U/ml penicillin/streptomycin. The cells were cul-
tured in 75 mm2 tissue culture flasks in a 5% CO2 humid-
ified incubator at 37°C.
Purification of primary ovarian carcinoma cells
Ascites fluid samples from seven patients diagnosed with
stage III or IV ovarian carcinoma, and one patient with
primary peritoneal carcinoma (PPC), were obtained
through the University of Minnesota Cancer Center Tissue
Procurement Facility with approval of the University of
Minnesota Institutional Review Board. All patients were
newly diagnosed, and had not been treated with chemo-
therapy prior to our receipt of the samples, as determined
by medical records. Ascites tumor cells and spheroids
were collected by centrifugation at 100 × g for 10 minutes.
Erythrocytes were lysed by resuspending the cells in lysis
buffer (10 nM potassium bicarbonate, 155 mM ammo-
nium chloride, 0.1 mM EDTA, pH 7.4) for 5 minutes. The
remaining cells were collected by centrifugation at 100 ×
g for 10 minutes, then layered upon Ficoll-Paque Plus
(Pharmacia Biotech, Uppsala, Sweden) and centrifuged
again at 400 × g for 15 minutes. The tumor cells were
removed from the top of the Ficoll layer and washed in
RPMI 1640 media. Aliquots of tumor cells (1 × 107 cells/
ml) were suspended in 10% DMSO and 90% FBS, and
stored in liquid nitrogen. The patient sample numbers
used in this study correspond to the patient sample num-
bers assigned in our previous publication [23].
Immunohistochemistry
Immunohistochemical verification was performed on all
ascites samples received. Briefly, paraffin blocks were
made from thrombin clots of ovarian carcinoma patient
ascites cells following purification. Thrombin clots were
prepared by adding 2–3 µl of the ascites cell pellet to 100
µl of human plasma and 50 µl thrombin (Sigma Chemi-
cal Co). The thrombin clots were fixed with 10% formal-
dehyde in PBS, and were paraffin-embedded by the
Fairview University Medical Center Pathology Laboratory.
4–5 micron sections were stained with a panel of antibod-
ies against ovarian carcinoma (CA-125), epithelial cells
(Ber-Ep4, CD15, B72.3, CEA), mesothelial cells (cal-
retinin), and inflammatory cells (CD45) on an automated
immunostainer (Benchmark, Ventana Medical Systems).
A pathologist evaluated each sample and verified the pres-
ence of 90% tumor cells in all cases.
Isolation of spheroids
In order to separate the spheroids from the single ovarian
cancer tumor cells, an aliquot of ascites tumor cells was
defrosted and rinsed with media, then filtered through a
22 µM cell-strainer cap fitted over a 5 ml tube (Becton
Dickinson, Franklin Lakes, NJ.) Spheroids retained in the
filter were gently rinsed into a collection tube, centrifuged,
and resuspended in RPMI media to the desired concentra-
tion. We define a spheroid as a cell aggregate of approxi-
mately 30–100 µM in diameter. It was usually not
possible to visualize one cell from the next in these aggre-
gates, and when sectioned, they were solid throughout
(no hollow centers). While the exact number of cells per
spheroid varied, they ranged from 10–20 cells up to over
one hundred cells in composition.
Spheroid disaggregation assay
96-well plates were coated overnight at 37°C with 5 µg/
ml laminin, fibronectin, type I collagen, type IV collagen,
hyaluronan, and BSA in PBS. The wells were then blocked
for 1 hour with 2 mg/ml BSA in PBS and then rinsed twice
with PBS. A concentration of 5–10 spheroids was added to
each of the coated wells. From our previous studies, we
determined that 1 hour was an appropriate time for sphe-
roids to begin adhering to an ECM matrix [23,24]. We
thus set t = 0 as 1 hour from the initial plating, so that if
the plate was not disturbed, the spheroids would not
move from their location at the time of plating. Spheroids
were digitally photographed at t = 0, incubated at 37°C
for 24 hours, and then re-photographed. To track individ-
ual spheroids over time, a map of the well was created at t
= 0. Reference to the map and the prior time point photo-
graph allowed individual spheroids to be tracked for the
duration of the assay. The pixel area of the spheroids at
both time points was determined using Adobe Pho-
toshop. The total area included the area of the disaggre-
gated spheroid plus the area of any dispersed single cells
in the near vicinity that were most likely to have come
from the disaggregated spheroid. Spheroid disaggregation
was determined as the fold change in pixel area of the
spheroids from 0 to 24 hours. The assay was limited to 24
hours as spheroids did not thrive past 24 hours without
sera. Values shown represent the average percent increase
in surface area of spheroids from three separate experi-
ments, totalling 20–40 spheroids, ± standard error.
Spheroid dissemination and invasion assay
To assess invasion, LP9 human mesothelial cells at 35,000
cells/well were added to 96-well plates and allowed to
grow to confluence for 96 hours, then were gently rinsed
with RPMI. Ascites spheroids were resuspended in com-
plete media to obtain 5–10 spheroids/ml, and 1 ml of the
suspension was added to each well atop the mesothelial
cell monolayers. Spheroids were digitally photographed 1
hour after plating, and then were incubated at 37°C. The
spheroids were photographed again at time-points of 1, 4,
and 7 days. Spent media was replaced every three days to
prevent the well from becoming too acidic. Two thirds of
the media was removed from the top of the well without
agitating the mesothelial cell monolayers and wasJ
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Table 1: Patient information.
Patient # 2345689 1 0
Diagnosis Poorly 
differentiated 
papillary serous 
adenocarcinoma
Papillary serous 
adenocarcinoma
Primary peritoneal 
carcinoma with 
invasive implants
Poorly 
differentiated 
serous papillary 
carcinoma
Serous papillary 
carcinoma
Serous papillary 
carcinoma
Metastatic serous 
adenocarcinoma
Poorly 
differentiated 
adenocarcinoma
Stage I I I CI I I CI I I CI I I CI I I CI I I CI I I C I V
Grade 32233233
Initial CA125 860 168 1950 2800 366 640 191 6640
Debulking optimal optimal optimal suboptimal optimal optimal optimal
Treatment 6 cycles Carbo/
Taxol
6 cycles Carbo/
Taxol
CDDP/Taxol Failed several 
chemos: Taxol, 
Carbo, Gemzar
Taxol/Carbo 1 
cycle
4 drugs/8 cycles 6 cycles (x2) 
Carbo/Taxol,
6 cycles Carbo/
Taxol
Surgery to 
Recurrence 
(Months)
22 36 8 Progressive disease Progressive disease 11 18 14
Overall Survival 
(Months)
39 Alive with disease 16 17 1 Alive with disease Alive 34
Age at diagnosis 58 45 63 70 75 29 70 52
Family History Aunt-breast cancer Mother-ovarian, 
breast cancer; 
maternal 
grandmother-
breast cancer; 
aunt-breast cancer
Mother-ovarian 
cancer; paternal 
aunt (x2)-breast 
cancer; maternal 
great aunt-
gynecological 
cancer
Sister-breast 
cancer
Grandmother-
uterine cancer; 
aunt-breast cancer; 
great aunt (x4)-
gynecological 
cancer; 
grandmother-
ovarian cancer
Patient data was obtained for seven advanced-stage ovarian carcinoma patients and one patient and one patient with primary peritoneal carcinoma. The patient numbers listed correspond with 
the patient numbers in all subsequent experiments.Journal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
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replaced with fresh media. Care was taken to avoid dis-
rupting the wells, and they were inspected carefully before
and after media changes to ensure spheroids were not lost.
To track individual spheroids over time, a map of the well
was created at t = 0. Reference to the map of the well and
the prior time point photograph allowed individual sphe-
roids to be tracked for the duration of the assay. Spheroid
dissemination was defined as spheroid disaggregation
and spreading on top of the mesothelial cell monolayers
without forming invasive foci. Spheroid invasion was
defined as the establishment of proliferating foci of ovar-
ian cancer cells within the same plane as the mesothelial
cell monolayers, such that the mesothelial cell monolay-
ers were pushed aside while the disaggregated spheroid
proliferated and grew laterally. Visualization of invasion
was achieved by light microscopy without the need for
separate labeling of the cells, as the invading ovarian can-
cer cells were within the same plane of focus as the mes-
othelial cell monolayers, while cells overlying but not
invading the monolayer appeared as a dense cell layer that
was slightly out of focus. Both spheroid dissemination
and invasion were quantified by calculating the fold
change in area, determined by dividing the pixel area of
the spheroids at each time point by the spheroid pixel area
at t = 0. The data represent the average fold change in area
of 50–100 spheroids ± standard error, from a total of four
separate experiments for each patient sample.
Cell proliferation and viability
Ascites spheroid and mesothelial cell monolayer viability
and proliferation were determined using a WST-1 assay
(Roche Applied Science, Indianapolis, IN.) WST-1 is a
tetrazolium salt cleaved to form a formazan dye by mito-
chondrial dehydrogenase activity. Approximately 20–50
Disaggregation of ascites spheroids on ECM components Figure 1
Disaggregation of ascites spheroids on ECM components. Ascites spheroids from eight patients were plated on laminin 
(black bars), fibronectin (striped), type I collagen (white), type IV collagen (light gray), hyaluronan (stippled), or BSA (dark gray) 
for 24 hours. Values represent the average percent increase in area of spheroids from triplicate experiments, ± standard error; 
* designates p-values < 0.05.Journal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
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Ascites spheroids demonstrate variable disaggregation on ECM components Figure 2
Ascites spheroids demonstrate variable disaggregation on ECM components. Patient ascites spheroids were photo-
graphed on various ECM components at t = 0 and 24 hours later. Ascites spheroids demonstrated variable migration in 
response to ECM components. The top panels show outgrowth of patient 9 spheroids on fibronectin, which is representative 
of the extent of disaggregation for most patient spheroid samples. The middle panels show a spheroid from patient 4 totally 
disaggregating on type I collagen. The bottom panels show two spheroids, indicated by arrows, from patient 3 on type I colla-
gen, with one spheroid completely disaggregated (left) and one unaltered (right). Magnification = 400×.Journal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
Page 7 of 16
(page number not for citation purposes)
Ascites spheroids show low levels of proliferation on ECM components in 24 hours Figure 3
Ascites spheroids show low levels of proliferation on ECM components in 24 hours. Patient ascites spheroid sam-
ples were added to 96 well plates coated with laminin (LMN), fibronectin (FN), type I collagen (CI), type IV collagen (CIV), 
hyaluronan (HA), or BSA. At 0 hours (black bars) and 24 hours (white bars), WST-1 was added for 3 hours and then the plates 
were read on a microplate reader at A440. Values represent the average of four wells ± standard deviation; * designates p-val-
ues < 0.05.Journal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
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spheroids were plated on ECM components or mesothe-
lial cell monolayers as described above, in 100 µl of media
per well. ECM components with media alone, or mes-
othelial cells alone, respectively, were used as controls. At
0 and 24 hours with the ECM assays, or at 0, 1, 4, and 7
days in the mesothelial cell assays, 10 µl of WST-1 was
added to the wells, incubated at 37°C for 3 hours, and the
absorbance of each well was read at 440 nm on a Spec-
traMax Plus384 microplate reader (Molecular Devices, Sun-
nyvale, CA.) Each experiment was repeated in
quadruplicate.
Spheroid and mesothelial cell monolayer viability was
also determined using an Annexin V-FITC Apoptosis
Patient ascites spheroids #2–5 disaggregate on or invade mesothelial cell monolayers Figure 4
Patient ascites spheroids #2–5 disaggregate on or invade mesothelial cell monolayers. Patient ascites spheroids 
were added to confluent mesothelial monolayers for 7 days to determine their invasive potential. Photos show representative 
examples of patient samples 2, 3, 4, and 5 at t = 0, and days 1, 4, and 7. Arrows delineate the perimeters of disaggregating or 
invading spheroids. Magnification = 100×.Journal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
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Detection Kit (BioVision, Mountain View, CA.) Following
manufacturer's instructions, cells were labeled with
Annexin V-FITC and propidium iodide, and were
observed on a Nikon Eclipse E200 microscope using FITC
and rhodamine filters (Nikon, Kanagawa, Japan.) Apop-
tosis appeared as a halo of green at the plasma membrane,
with a red stain throughout the nucleus. Cells undergoing
apoptosis stained green in the plasma membrane but
showed no propidium iodide staining.
Statistical analysis
The student's t-test was performed as a test of significance
with the use of Microsoft Excel 2002 (Microsoft Co., Red-
mond, WA). P-values of < 0.05 were considered to indi-
cate statistically significant differences.
Patient ascites spheroids #6–10 disaggregate on mesothelial cell monolayers Figure 5
Patient ascites spheroids #6–10 disaggregate on mesothelial cell monolayers. Patient ascites spheroids were added 
to confluent mesothelial monolayers for 7 days to determine their invasive potential. Photos show representative examples of 
patient samples 6, 8, 9, and 10 at t = 0, and days 1, 4, and 7. Arrows delineate the perimeters of disaggregating spheroids. Mag-
nification = 100×.Journal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
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Results
Ascites spheroids disaggregate on ECM components
Spheroids were isolated from the ascites of seven patients
with stage III and IV ovarian carcinoma and one patient
with primary peritoneal carcinoma. A pathologist evalu-
ated the samples by immunohistochemistry prior to use
in assays to verify that each sample matched its diagnosis.
Diagnosis, initial CA125 levels, treatment, family cancer
history and survival data for the eight patients are
included in Table 1. In a previous study from our lab, the
adhesivity of these same eight patient ascites samples was
tested on various ECM components and live human mes-
othelial cell monolayers [23]. Here, these ascites spheroid
samples were tested for their ability to disaggregate on
ECM components. In disaggregation, the spheroids trans-
form from a three-dimensional cell cluster to a flat plaque,
as the cells migrate out of the spheroid and dismantle
their cell-cell contacts to adhere to and spread on the
ECM. 5–10 ascites spheroids were suspended in RPMI and
added to each well of a 96-well plate (Fig. 1) coated with
5  µg/ml of laminin (black bars), fibronectin (striped
bars), type I collagen (white bars), type IV collagen (light
gray bars), hyaluronan (stippled bars), or BSA (dark gray
bars) for 24 hours. The spheroids were photographed at
the time of plating (t = 0) and again at 24 hours. The fold
change in area was calculated by dividing the pixel area of
the spheroid at 24 hours by the pixel area at t = 0. Any fold
change in area beyond 1 was considered to be significant.
In general, ascites spheroids tended to slightly disaggre-
gate on all ECM components, forming a looser spheroid
whose cells did not usually flatten or spread to form a
monolayer (Fig. 2, top panel). The resulting spheroid sur-
face area after 24 hours typically increased 30–50%, with
disaggregation preferentially occurring on type IV colla-
gen and type I collagen. However, individual ascites sphe-
roid samples sometimes demonstrated a greater ability to
spread overall, or spread effectively only on specific ECM
components. For example, while spheroids from patients
3 and 8 increased in surface area 60% after 24 hours on all
ECM components tested, sample 3 preferred type IV colla-
gen and hyaluronan, nearly doubling in size (Fig. 1). Type
IV collagen also elicited a near doubling in size from sam-
ple 8, as did fibronectin and type I collagen. Samples 6
and 9 both showed about a 40% increase in size, with
sample 6 spreading best on laminin, while sample 9
spread similarly on type I collagen, type IV collagen, and
fibronectin (Fig. 1). Sample 4, the primary peritoneal car-
cinoma, exhibited the most dramatic increase in spread-
ing, as it disaggregated extensively on type I collagen more
than any other ascites spheroid samples tested (Fig. 1).
Samples 2, 5, and 10 showed an average of less than 30%
spreading on all ECM components, with few exceptions
(Fig. 1).
In some cases, individual spheroids exhibited disaggrega-
tion properties that differed from the majority of sphe-
roids in a patient's sample. Thus, even when a majority of
a patient's spheroids disaggregated on most ECM mole-
cules, some of the patient's spheroids would not disaggre-
gate or spread. For instance, most of the spheroids from
patient 4 demonstrated extensive disaggregation on type I
collagen (Fig. 2, middle panel), however some spheroids
from this patient did not disaggregate on type I collagen at
all. Even within the same well, individual spheroids from
the same patient behaved quite differently in response to
ECM components. As an example, Figure 2 (bottom
panel) shows two spheroids from patient 3 plated on type
I collagen. The spheroid on the left completely disaggre-
gated, while the spheroid on the right in the same well did
not disaggregate at all. Samples that spread 2-fold or more
on any ECM component constituted less than 10% of the
total number of spheroids tested for each patient sample.
Spheroid proliferation on ECM components was tested by
the cell proliferation agent WST-1 (Fig. 3.) WST-1 readings
of ascites samples were compared at 0 and 24 hours, and
also to control wells with no spheroids added. Most sphe-
roids did not appreciably proliferate over 24 hours. How-
ever, the amount of significant proliferation (p-values <
0.05) seen for individual patient samples sometimes cor-
related to the ECM components upon which they spread
the most. For example, patient samples 2, 6, 8, and 10
showed some proliferation on the ECM components on
Ascites spheroids disaggregate on mesothelial cell monolay- ers Figure 6
Ascites spheroids disaggregate on mesothelial cell 
monolayers. Ascites spheroids from eight patients were 
plated on confluent mesothelial cell monolayers for seven 
days. The fold change in spheroid area was calculated at day 
7. Bars represent the percentage of the total number of 
spheroids that disaggregated 2.0 to 4.9 fold (black), 5.0 to 7.9 
fold (white), 8.0 to 10.9 fold (gray), or greater than 11.0 fold 
(striped) in area over seven days. P-values were < 0.05 for all 
samples at all time points, with the exception of samples 8 
and 10 at day 1.Journal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
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which they most effectively disaggregated. Sample 3
showed a correlation only on hyaluronan, and sample 9
only on type IV collagen and BSA. In contrast, sample 4
proliferated on fibronectin and hyaluronan even though
spheroids from this patient spread extensively on type I
collagen. Sample 5 showed no proliferation on any ECM
component tested. Taking into account the low levels or
lack of proliferation observed, these data suggest that the
majority of cells comprising patient ascites spheroids tend
to disaggregate and spread rather than proliferate on most
ECM components in a period of time limited to 24 hours.
Ascites spheroids disseminate on mesothelial cell 
monolayers
The most common site of metastasis in ovarian carcinoma
is the peritoneum, which is lined by a monolayer of mes-
othelial cells. To investigate the ability of ovarian carci-
noma spheroids to invade mesothelial cells, invasion
assays were performed with ascites spheroids from eight
patients. 5–10 ascites spheroids were added to each well
of a 96-well plate containing live, confluent human mes-
othelial cell monolayers, and were incubated for 7 days.
The ascites spheroids were photographed at the time of
plating (t = 0) and again at days 1, 4, and 7 (Figs. 4 and 5).
Disaggregation and invasion was measured as the fold
change in pixel area at each time point relative to the pixel
area at t = 0.
Frequently, the area of dissemination was visible as a dark
discoloration across the top of the monolayer. Upon
inspection at a higher magnification, this discoloration
was determined to be the dissemination of individual
tumor cells from the disaggregated spheroid. In most
cases, the areas of dissemination did not significantly
increase when assays were extended to 10 days.
In general, the ascites spheroids initially increased in size,
and then disaggregated on the mesothelial cell monolay-
ers over a period of seven days. Typically, the spheroids
did not fully disaggregate in the first 24 hours, although
their size increased, suggesting either proliferation or
loosening of intercellular contacts. WST-1 assays of ascites
spheroid proliferation on mesothelial monolayers, how-
ever, were unable to conclusively demonstrate spheroid
proliferation (data not shown), suggesting that the
enlarged spheroid areas were due to partial disaggrega-
tion. By day 4 nearly 50% of the spheroids disaggregated
and spread to occupy a surface area that was double their
initial size, and had more than tripled in size by day 7
(Figs. 4 and 5). About 50% of the spheroids tested over
the course of the assay simply enlarged without disaggre-
gating, demonstrating typically a 2-fold change in size at
most. The majority of disseminated spheroids spread
between 2 fold and 4.9 fold by day 7 (Fig. 6.) In general,
only 5–15% of the spheroids displayed disseminated
areas greater than 5 fold. Patient sample 4 showed the
greatest amount of dissemination on top of the mesothe-
lial cell monolayers, with more than 30% of the spheroids
showing a change greater than 5-fold, and 5% of the sphe-
roids exhibiting changes greater than 11-fold (Fig. 6). In
contrast, the majority of ascites spheroids from patients 8
and 9 disaggregated and spread less than 5 fold, with only
2–5% of spheroids spreading more than 5 fold (Fig. 6).
Data was statistically significant (p-value < 0.05) for all
patient samples at all time points, with the exceptions of
patient samples 8 and 10 at day 1.
Previous studies have suggested that the condition of the
mesothelium may affect tumor cell invasion [26]. It was
often noted during our assays that the morphology of the
mesothelial cell monolayer surrounding the area of ascites
Ascites spheroids affect the confluence of mesothelial cell monolayers Figure 7
Ascites spheroids affect the confluence of mesothelial cell monolayers. (A) The ascites spheroids added to the inva-
sion assays frequently caused areas of sparseness to develop in the area of the mesothelial cell monolayer upon which they 
were attached. This usually increased up to day 4, but disappeared by day 7. Arrows indicate ascites spheroids. Magnification = 
100×.Journal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
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spheroid attachment altered, growing less confluent and
revealing bare patches of tissue culture plastic (Fig. 7).
This occurred for about 25% of the spheroids tracked in
our assays. However, these sparse areas typically filled in
again by day 7, suggestive of mesothelial cell prolifera-
tion. Proliferation assays with WST-1 showed that the
mesothelial cells, when cultured alone, indeed proliferate
up to 7 days, implying that they may be able to repopulate
sparse areas during the course of the assay.
To test their viability, ascites spheroids and mesothelial
monolayers were stained with an Annexin V-FITC kit (Fig.
Ascites spheroids and mesothelial cell monolayers are viable for 7 days Figure 8
Ascites spheroids and mesothelial cell monolayers are viable for 7 days. Ascites spheroids from eight patients were 
plated on confluent mesothelial cell monolayers in 96-well plates for seven days. At days 0, 1, 4, and 7, wells were stained with 
Annexin V-FITC and propidium iodide. Panels shows confluent mesothelial monolayers alone (lef column) or with patient 
ascites sample 3 at day 4 (middle column) or day 7 (right column) with a bright-field image (row 1), Annexin V-FITC staining 
(row 2), and propidium iodide staining (row 3). Arrows delineate the perimeters of ascites spheroids that have attached and 
spread on the mesothelial cell monolayer. Magnification = 100×.Journal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
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8.) Cells undergoing apoptosis stained green with
Annexin V-FITC, while cells that had already apoptosed
stained red with propidium iodide, and sometimes
showed a faint green halo of Annexin V-FITC. In general,
the patient ascites spheroids remained alive for the dura-
tion of the assays as evidenced by lack of Annexin V and
propidium iodide staining, although occasional apopto-
sis was observed for some individual cells comprising the
spheroids. Representative examples from patient sample 3
demonstrate the apoptosis seen in some individual cells
of the ascites spheroids and single tumor cells (Fig. 8, mid-
dle column) but overall the spheroids remained alive
throughout the assay (Fig 8, right column.) Little apopto-
sis occurred in mesothelial cell monolayers over 7 days
(Fig 8, left column.)
Despite their ability to attach and spread across the mes-
othelial cell monolayers, it was rare to see foci of invasion
form or extensive proliferation of the ascites spheroid
cells. However, we did note ascites spheroids that deviated
in behavior. Specifically, about 15% of the ascites sphe-
roids from samples 4 and 5 disaggregated, invaded, and
appeared to have proliferated in the mesothelial cell mon-
olayers (patient sample 5 shown in Fig. 9). Invasive ascites
spheroids constituted about 5% of the total number of
spheroids tested in patient samples, but nevertheless,
these data suggest the ascites may contain subclones of
spheroids with an invasive potential.
Discussion
The dissemination of ovarian carcinoma occurs via shed-
ding of cells from the primary tumor with subsequent
seeding of the peritoneal cavity, followed by invasion and
proliferation at the secondary site. Because widespread
peritoneal implantation and advanced disease can often
occur without hematogenous spread, determining the
invasive potential of the ascites cellular contents is critical.
In earlier studies from our lab, we demonstrated that
spheroids created from the NIH:OVCAR5 ovarian carci-
noma cell line could adhere to and disaggregate on ECM
components, adhere to live mesothelial cells, and exten-
sively invade into live mesothelial cell monolayers
[22,24]. Follow-up experiments with ascites spheroids
from ovarian carcinoma patients demonstrated that they,
too, could adhere to ECM components as well as live mes-
othelial cell monolayers [23].
In this study, we determined the ability of eight patient
ascites spheroid samples to disaggregate on ECM compo-
nents and invade mesothelial cell monolayers. Patient
ascites spheroids typically exhibited some disaggregation,
with cells migrating out of the spheroid when placed on a
variety of ECM components. The majority of the ascites
spheroids increased in surface area on all ECM compo-
nents tested. In our previous study, NIH:OVCAR5 sphe-
roids completely disaggregated on type I collagen,
showing a 6-fold increase in surface area over 24 hours
[24]. Here, none of the five ECM components tested
induced extensive disaggregation (i.e. more than a 2-fold
change in size). Furthermore, the disaggregation seen on
ECM components typically was not accompanied by
abundant proliferation, although proliferation of particu-
lar patient samples sometimes appeared to correlate to the
ECM component on which they spread most effectively.
While the levels of patient ascites spheroid disaggregation
shown here were not as extensive as the NIH:OVCAR5
spheroids, several possibilities exist to explain this differ-
ence. First, NIH:OVCAR5 spheroids were formed in vitro
over a 48-hour period while ascites spheroids may exist
Patient ascites spheroids are capable of invading a live human mesothelial cell monolayer Figure 9
Patient ascites spheroids are capable of invading a live human mesothelial cell monolayer. An ascites spheroid 
from patient 5 is shown invading into a mesothelial cell monolayer. The arrows delineate the area of spheroid invasion and pro-
liferation within the mesothelial cell monolayer. Magnification = 400×.Journal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
Page 14 of 16
(page number not for citation purposes)
for lengthy periods of time in vivo. Thus, patient spheroids
may develop extensive cell-cell connections that hinder
their ability to disaggregate. Because the ascites spheroid
isolation process and subsequent assays require frequent
pipetting, filtering, and centrifugation, any spheroids that
would disaggregate upon mechanical stimulation are
likely to be eliminated from our sample pool, leaving only
those spheroids resistant to mechanical disruption and
more tightly aggregated. It is possible that the contacts
facilitating strong aggregate cohesion may translate to a
decreased ability to disaggregate on ECM surfaces. Studies
have identified cadherins, desmosomes, tight junctions,
gap junctions, and a variety of ECM components includ-
ing laminin, fibronectin, collagen, and glycosaminogly-
cans in the cell-cell contacts of spheroids, any of which
may hinder their ability to disaggregate upon an extracel-
lular surface [27-31]. Our previous studies have shown
that NIH:OVCAR5 spheroids are held together by
fibronectin interacting with the α5β1 integrin [22]. Addi-
tionally, the patients' spheroids may incorporate mole-
cules such as ECM proteins from the ascites fluid,
enabling them to adhere together more tightly or form a
matrix that blocks receptors necessary to mediate migra-
tion.
Interestingly, some of the spheroids present in patient
samples disaggregated quite dramatically on specific ECM
components. Ascites spheroids from patient 4 often
exhibited complete disaggregation on type I collagen.
However, not every spheroid from this patient disaggre-
gated. In fact, spheroids plated in the same well com-
monly demonstrated differing disaggregation capabilities.
This variable response to ECM components suggests that
some spheroids within the ascites may develop a meta-
static phenotype that attenuates their ability to respond to
molecules within their environment. These results may
reflect the heterogeneity often seen in solid tumors, where
only a few subclones of tumor cells are capable of metas-
tasis.
Previous studies from our lab showed that NIH:OVCAR5
spheroids could invade live monolayers of mesothelial
cells, establishing foci of invasion that increased in size up
to 200-fold in a week [24]. Here, ascites spheroids from all
eight of the patient samples tested were capable of disag-
gregating on mesothelial cell monolayers or their exposed
ECM, typically without actively invading. This is similar to
the situation in vivo, where tumor cells extensively dissem-
inate throughout the peritoneum without evidence of
invading at the time of the first surgery. This suggests that
our in vitro model accurately mimics in vivo conditions.
However, some ascites spheroids were able to invade into
and proliferate within a mesothelial cell monolayer, also
suggesting that a portion of the spheroids in the ascites
may constitute an invasive threat.
In those patient samples that demonstrated a more inva-
sive phenotype in our study, not every spheroid was capa-
ble of disaggregating and invading. Ascites spheroids
plated in the same well did not exhibit the same invasive
properties despite sharing an identical environment. In
fact, only a few spheroids established foci of invasion.
This data implies that the invasive behavior of the ascites
spheroids was not merely induced by the spheroids'
microenvironment, but likely relied on physiological dif-
ferences in the spheroids' invasive characteristics. It is
widely known that tumors are heterogeneous, and tumor
cells can differ greatly in their metastatic potential, such
that only a few cells in the primary tumor will become
metastatic [32-35]. From the data presented here, it is
clear that these same conditions may apply to spheroids
in ovarian carcinoma effusions. Further studies where
invasive and non-invasive ascitic ovarian carcinoma cells
are isolated may allow for the determination of specific
characteristics of metastatic cells.
Application of WST-1 to dissemination and invasion
assays did not allow a determination to be made regard-
ing spheroid proliferation on mesothelial cells. Based on
the design of the dissemination and invasion assay, the
confluent mesothelial cells greatly outnumbered the
spheroids in each well. When we added an overabun-
dance of spheroids to each well (100–1000 spheroids in
an effort to measure spheroid proliferation, we observed a
negative impact on mesothelial cell survival. It is possible
that only a few spheroids per sample may be significantly
proliferative. As only 5% of the total spheroids were capa-
ble of invasion, it would be difficult to detect a prolifera-
tive spheroid in the WST-1 assay. While the spheroids may
not substantially proliferate, they are viable throughout
the assay as shown by lack of Annexin V and propidium
iodide staining. Some individual cells of the spheroids
underwent apoptosis, but the bulk of the spheroids
remained alive. When initially recovered from the
patients, some of the cells comprising the spheroids were
already dead for unknown reasons. It is possible that the
one-time freezing and thawing process led to further dam-
age of some cells. However, trypan blue staining of the
spheroids during culture revealed that the majority of the
cells comprising the spheroids were alive. Thus, while
many of the spheroids may not have actively proliferated
on the mesothelial cell monolayers, their survival alone
still would permit seeding of the mesothelium, which
could ultimately result in the development of an invasive
subclone.
Of interest, ascites spheroid samples 4 and 5 exhibited the
most invasive characteristics in vitro, correlating with these
patients' shortened overall survival of 16 and 17 months,
respectively. It is noteworthy that patient 4, the only sam-
ple cultured from a patient with primary peritoneal cancerJournal of Translational Medicine 2006, 4:6 http://www.translational-medicine.com/content/4/1/6
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(PPC), exhibited some of the most invasive characteristics
of any spheroids tested. PPC is thought to have a similar
biology as ovarian cancer, and the diseases are often con-
sidered to be the same. It is tempting to speculate from
our evidence here that PPC ascites spheroids may be more
invasive than ovarian carcinoma spheroids, although
future studies with additional patient samples will be nec-
essary to identify significant differences in the invasive-
ness of these two cancers.
In our invasion assays, it was sometimes noted that the
confluence of the mesothelial cell monolayers was dis-
rupted. This typically occurred in the area surrounding an
attached spheroid, leading one to speculate whether fac-
tors that the spheroids secrete or induce, such as pro-
teases, may be responsible for this effect. As this effect
often disappears by day seven, it is possible that it is a
transient effect terminated upon spheroid cell dispersal,
allowing the mesothelial cells to proliferate in the dam-
aged area. Indeed, both matrix metalloproteinases and
plasminogen activators have been identified in ovarian
cancer [36-41]. Intriguingly, similar to our in vitro obser-
vations, in some ovarian carcinoma patients the perito-
neal mesothelium that normally serves as a non-adhesive,
protective barrier can become altered, resulting in thicken-
ing, vascularity, edema, hyperplasia, and fibrosis [26].
While the cause remains undetermined, a compromised
mesothelium may enhance invasion of ovarian carcinoma
ascites cells by exposing underlying basement matrices to
which the tumor cells can adhere. In support of this, stud-
ies have shown that ovarian tumor cells frequently attach
to the spaces between mesothelial cells where the under-
lying ECM is exposed, subsequently leading to mesothe-
lial cell exfoliation and the establishment of invasive foci
[42-44]. While one limitation of our study is that it does
not show whether invasion is due to mesothelial cell
death or exfoliation, our observations with Annexin V
staining suggest that the mesothelial cells are alive for the
duration of the assay, even when in contact with tumor
cells.
Conclusion
The cellular changes essential for the progression of ovar-
ian carcinoma remain unknown. As little is understood
about the ascitic tumor cells and the characteristics neces-
sary to promote their invasive growth, the fact that these
cells are often dismissed as non-metastatic is somewhat
disquieting. We show here that uncultured ascites sphe-
roid samples from ovarian carcinoma and primary perito-
neal carcinoma patients are able to disaggregate on ECM
components and human mesothelial cells monolayers,
and are sometimes capable of invasion. Based on our
data, the biology of the ascites cellular content should be
investigated to develop a more comprehensive under-
standing of the dissemination of ovarian carcinoma.
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